ClinVar Miner

Submissions for variant NM_006493.4(CLN5):c.265G>A (p.Asp89Asn)

gnomAD frequency: 0.00034  dbSNP: rs138110438
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000726905 SCV000240625 uncertain significance not provided 2023-08-30 criteria provided, single submitter clinical testing In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 28492532)
Eurofins Ntd Llc (ga) RCV000726905 SCV000704082 uncertain significance not provided 2017-01-08 criteria provided, single submitter clinical testing
Invitae RCV000698534 SCV000827202 uncertain significance Neuronal ceroid lipofuscinosis 2024-01-22 criteria provided, single submitter clinical testing This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 138 of the CLN5 protein (p.Asp138Asn). This variant is present in population databases (rs138110438, gnomAD 0.09%). This variant has not been reported in the literature in individuals affected with CLN5-related conditions. ClinVar contains an entry for this variant (Variation ID: 205129). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CLN5 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV002314702 SCV000847655 uncertain significance Inborn genetic diseases 2017-06-21 criteria provided, single submitter clinical testing The p.D138N variant (also known as c.412G>A), located in coding exon 2 of the CLN5 gene, results from a G to A substitution at nucleotide position 412. The aspartic acid at codon 138 is replaced by asparagine, an amino acid with highly similar properties. This amino acid position is not well conserved and asparagine is the reference amino acid in several species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this variant remains unclear.
Athena Diagnostics Inc RCV000726905 SCV001143614 uncertain significance not provided 2018-11-20 criteria provided, single submitter clinical testing
Genome-Nilou Lab RCV001272143 SCV002027059 uncertain significance Neuronal ceroid lipofuscinosis 5 2021-09-05 criteria provided, single submitter clinical testing
Fulgent Genetics, Fulgent Genetics RCV001272143 SCV002788355 uncertain significance Neuronal ceroid lipofuscinosis 5 2021-10-13 criteria provided, single submitter clinical testing
Natera, Inc. RCV001272143 SCV001453812 uncertain significance Neuronal ceroid lipofuscinosis 5 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.